Massive ICU trial aims to settle debates on blood pressure, platelets, and nutrition
NCT ID NCT06605144
First seen Jun 26, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study, called CEPEC, is a large platform trial enrolling 5,500 ICU patients across multiple countries. It tests different approaches to three common ICU treatments: how low to let blood pressure go with vasopressors, when to give platelet transfusions, and how to provide nutrition. The goal is to find out which strategies lead to better survival and recovery. By comparing treatments already used in practice, the results could directly guide doctors' decisions in the ICU.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Vasopressors, platelet transfusions, and nutrition interventions
- What this could lead to
- If successful, this trial could help doctors make better decisions about routine ICU care, potentially improving survival and recovery for critically ill patients.
- What could go wrong
- This is a large, pragmatic trial, but results may not apply to all ICU patients. The interventions are already in use, so no major new risks are expected, but the study may not find clear winners among the options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 5,500 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Jun 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
VASOPRESSOR DOMAIN There is no minimum age limit in the Vasopressor Domain. Inclusion criteria: 1. Ongoing vasopressor infusion to treat hypotension, or would be used to treat clinician-defined hypotension as part of usual care; 2. MAP \<75 mmHg at any point; 3. Patient expected to be in the ICU for \>24 hours. Exclusion criteria: 1. Treating team does not have equipoise for at least two contiguous MAP target ranges in the CEPEC Vasopressor Domain; 2. Acute traumatic brain injury (within 7 days or ongoing active treatment for elevated intracranial pressure); 3. Acute subarachnoid hemorrhage (within 21 days); 4. Acute spinal cord injury (within 7 days of injury or ongoing vasopressor therapy for suspected spinal cord ischemia); 5. Lung, heart, liver, kidney transplant recipient (within 7 days); 6. Patient expected to become an organ donor (Donor Neurologic Death - DND or Donation After Circulatory Death - DCD); 7. More than 24 hours since meeting inclusion criteria in the ICU; 8. Previously randomized into the CEPEC Vasopressor Domain or a confounding trial. PLATELET DOMAIN Inclusion criteria: 1. Adult patients (age ≥18 years) admitted to the ICU; 2. Latest platelet count in this hospital admission \<50×109/L; 3. Planned to undergo a specified low-moderate bleeding risk invasive procedure. Exclusion criteria: 1. Ongoing major hemorrhage requiring blood products and/or surgical/ radiological intervention; 2. Intracranial hemorrhage within prior 72 hours; 3. Contraindications to platelet transfusion (e.g. thrombotic microangiopathies, heparin-induced thrombocytopenia, recent history of immune thrombocytopaenia, congenital platelet function defects); 4. Known advance decision of refusing blood/blood component transfusions; 5. Acute promyelocytic leukemia (APML); 6. Death perceived as imminent or admission for palliation; 7. Previously randomized into the CEPEC Platelet Domain or the T4P Trial; 8. Fulfilled all the inclusion criteria and none of the exclusion criteria ≥72 hours. NUTRITION DOMAIN Inclusion criteria: 1. Critically ill patients ≥18 years of age; 2. Are invasively mechanically ventilated (including endotracheal tube or tracheostomy); 3. Orogastric/nasogastric tube in place; or have an in dwelling percutaneous gastric tube (with confirmed placement); 4. Treating team has started or has the intention of providing enteral nutrition. Exclusion criteria: 1. Patients who have had gastrointestinal (GI) surgery; in the last 3 months and deemed not ready to receive possible bolus nutrition; 2. Bowel obstruction or ischemia; active; 3. Has a post-pyloric small bowel feeding tube; 4. Active GI bleeding; 5. Patient who is chronically receiving enteral nutrition.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular shock are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
9 sites in 3 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Auckland City Hospital
NOT_YET_RECRUITINGAuckland, New Zealand
-
CIUSSS de l'Estrie - CHUS
RECRUITINGSherbrooke, Quebec, J1H 5N4, Canada
-
Centre hospitalier de l'Université de Montréal (CHUM)
RECRUITINGMontreal, Quebec, H2X 0C1, Canada
-
Hamilton Health Sciences - Juravinski Hospital
RECRUITINGHamilton, Ontario, L8V 1C3, Canada
-
Intensive Care National Audit and Research Centre (coordinating centre for sites in UK. Sites to be determined)
NOT_YET_RECRUITINGLondon, United Kingdom
-
Niagara Health
RECRUITINGSt. Catharines, Ontario, L2S 0A9, Canada
-
Scarborough Health Network
RECRUITINGScarborough Village, Ontario, M1P 2V5, Canada
-
Sunnybrook Health Sciences Centre
RECRUITINGToronto, Ontario, M4N 3M5, Canada
-
The Ottawa Hospital
RECRUITINGOttawa, Ontario, K1H 8L6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sugar tracer reveals how immune cells fuel up in the ICU
- A diet tweak may boost platelets in a bleeding disorder
- Can almond, soy, or oat milk match dairy for nutrient absorption?
- Protein and saline mist may cut bleeding risk after tonsil removal
- Can a slower oxytocin infusion prevent dangerous blood pressure drops in C-Sections?
- Spinal stimulation may tame blood pressure swings after injury